SCHEMBL1827128

SCHEMBL1827128

CC(C(N)=O)c1ccc(OS(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.51
ADAMTS4 O75173 1/20 0.50
MAPT P10636 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ALDH1A1 P00352 1/20 0.44
ENPP3 O14638 5/20 0.44
ENPP1 P22413 5/20 0.44
ENPP2 Q13822 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CXCR2 P25025 2/20 0.43
EPHX1 P07099 1/20 0.43
CXCR1 P25024 1/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1345199 0.88 ADAMTS4 (0.55) TDP1ADAMTS4MAPTSMN1; SMN2NPC1
SCHEMBL2835298 0.88 ADAMTS4 (0.55) TDP1ADAMTS4MAPTSMN1; SMN2NPC1
SCHEMBL1345327 0.88 ADAMTS4 (0.55) TDP1ADAMTS4MAPTSMN1; SMN2NPC1
SCHEMBL1824947 0.87 KMT2A (0.51) MAPTALDH1A1ENPP3ENPP1ENPP2
SCHEMBL1824672 0.87 TDP1 (0.53) TDP1ADAMTS4MAPTSMN1; SMN2NPC1
SCHEMBL1828838 0.85 PTGS1 (0.50) TDP1ADAMTS4MAPTSMN1; SMN2ALDH1A1
SCHEMBL2834868 0.84 ADAMTS4 (0.52) TDP1ADAMTS4MAPTSMN1; SMN2NPC1
SCHEMBL1827634 0.84 TDP1 (0.53) TDP1ADAMTS4MAPTSMN1; SMN2NPC1
SCHEMBL1828064 0.83 TDP1 (0.49) TDP1ADAMTS4MAPTSMN1; SMN2NPC1
SCHEMBL2832246 0.82 TDP1 (0.48) TDP1ADAMTS4MAPTSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2161254-B1 Intermediate for preparing a biaryl compound SUMITOMO CHEMICAL CO (JP) 2014-08-13 EP disclosed
EP-1481967-B1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2011-05-04 EP disclosed
US-7714157-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-05-11 US disclosed
EP-2161254-A1 Intermediate for preparing a biaryl compound Sumitomo Chemical Company, Limited (JP) 2010-03-10 EP disclosed
US-20070270603-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-11-22 US disclosed
US-7271280-B2 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-18 US disclosed
EP-1481967-A1 PROCESS FOR THE PREPARATION OF BIARYL COMPOUNDS Sumitomo Chemical Company, Limited (JP) 2004-12-01 EP disclosed
US-20040158093-A1 Process for preparing a biaryl compound SUMITOMO CHEMICAL COMPANY, LIMITED 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040158093-A1 Process for preparing a biaryl compound CYP1B1, REL, CYP2F1 TDP1 4543/4885ADAMTS4 4799/4885MAPT 4712/4885
US-20070270603-A1 Process for preparing a biaryl compound CYP4A11, CYP4B1, CYP51A1 TDP1 4702/4885ADAMTS4 4532/4885MAPT 2237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.